World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Search
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Interstitial lung disease in rheumatoid arthritis (RA-ILD)
Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Quick response in fighting Foot-and-Mouth-Disease
Helping to contain an outbreak of the disease on the island of Rodrigues in just six days.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Have you heard about monkeypox
Monkeypox: What exactly is it, how is the virus transmitted, what are the most noticeable symptoms?
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Connect the Docs
Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Facts About IPF
IPF is a debilitating and fatal lung disease.
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Chronic kidney disease in cats
Detect and manage chronic kidney disease and high blood pressure in cats
GPP: there is more than you see
Generalized Pustular Psoriasis is a rare neutrophilic skin condition. Watch an animation to learn about its recurrent nature and how it affects people
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Bluetongue disease
The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.
Finding the right inhaler for you
Living with a chronic respiratory disease can make life complicated. This discussion guide can be used to help start a conversation with a healthcare professional about inhaler choice.
World Heart Day 2021
Cardiovascular diseases, including heart disease, are the leading cause of death and disability worldwide and are closely linked to kidney and metabolic diseases.
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.